AMYLOID BETA PEPTIDES, SOLUBLE OLIGOMERS COMPRISING AMYLOID BETA PEPTIDES, METHODS FOR IDENTIFYING COMPOUNDS SUITABLE FOR TREATMENT OF DISEASES UTILIZING AMYLOID BETA PEPTIDES OR SOLUBLE OLIGOMERS, METHODS FOR SELECTING BINDING PROTEINS REACTIVE WITH THE AMYLOID PEPTIDES OR SOLUBLE OLIGOMERS UTILIZING AMYLOID BETA PEPTIDES OR SOLUBLE OLIGOMERS, USE OF AMYLOID PEPTIDES OR SOLUBLE OLIGOMERS IN MANUFACTURE OF PHARMACEUTICAL COMPOSITIONS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE AMYLOID PEPTIDES OR SOLUBLE OLIGOMERS, VACCINES COMPRISING THE AMYLOID PEPTIDES OR SOLUBLE OLIGOMERS, NUCLEOTIDES ENCODING THE AMYLOID PEPTIDES, EXPRESSION SYSTEMS COMPRISING THE NUCLEOTIDES ENCODING THE AMYLOID BETA PEPTIDES, AND NON-HUMAN TRANSGENIC ANIMALS EXPRESSING THE NUCLEOTIDES ENCODING THE AMYLOID BETA PEPTIDES

摘要

PROBLEM TO BE SOLVED: To provide monomeric and oligomeric amyloid beta peptide isomers resistant to fibrillogenesis, uses thereof as a screening reagent or an antigen in methods and in pharmaceutical compositions for treating Alzheimer's disease and other conditions related to protein misfolding, as well as transgenic animals expressing the modified amyloid precursor proteins or amyloid beta peptides.SOLUTION: According to the invention, alanine residues at positions 21 and 30 of the wild type amyloid beta peptide amino acid sequence are replaced by cysteines, which results in an intramolecular disulfide bond.